Indocyanine Green Clearance Correlates With Biomarkers Reflecting Key Disease‐Driving Mechanisms in Advanced Chronic Liver Disease and Predicts Acute‐on‐Chronic Liver Failure and Death

Mathias Jachs(Medical University of Vienna), Mattias Mandorfer(Medical University of Vienna), Michael Schwarz(Medical University of Vienna), Tânia Carvalho(Unidade Hospitalar de Bragança), Nina Dominik(Medical University of Vienna), Paul Thöne(Medical University of Vienna), Benedikt Simbrunner(Austrian Academy of Sciences), Lukas Hartl(Medical University of Vienna), Matthias Pinter(Medical University of Vienna), Michael Trauner(Medical University of Vienna), Georg Semmler(University of Southern Denmark), Thomas Reiberger(ERN GUARD-Heart), Benedikt Hofer(Austrian Academy of Sciences), Albert Friedrich Stättermayer(Medical University of Vienna), Lorenz Balcar(Medical University of Vienna), Georg Kramer(Medical University of Vienna), Christian Sebesta(Medical University of Vienna), David Bauer(Austrian Academy of Sciences)
Alimentary Pharmacology & Therapeutics
November 5, 2025
10.1111/apt.70447
Cited by 3

Related Papers

NASH limits anti-tumour surveillance in immunotherapy-treated HCC
|Nature|2021|1.3k
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
|The Lancet|2023|514
Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFITY score
|Journal of Hepatology|2021|309
Cancer and liver cirrhosis: implications on prognosis and management
|ESMO Open|2016|287
Inflammasomes in chronic liver disease: Hepatic injury, fibrosis progression and systemic inflammation
|Journal of Hepatology|2024|239